80 terminated. 80 Phase 2, 22 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 80 | Terminated 80 |
| Phase 1 | 22 | Terminated 22 |
| Phase 3 | 3 | Terminated 3 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010) - Hematologic Malignancy | Phase 2 | Terminated | Prolacta Bioscience | 46 | 2023-09-18 | 2024-08-19 |
| Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies. Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG) - Hematologic Malignancy, Myeloid Malignancy | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2023-03-14 | 2025-10-02 |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Fludarabine, Cyclophosphamide, Thiotepa - Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2022-10-06 | 2025-01-01 |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 24 | 2021-12-17 | 2025-11-03 |
| Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials Screening Platform - Neoplasms | Phase 2 | Terminated | GlaxoSmithKline | 16 | 2021-12-16 | 2024-02-05 |
| A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma EMB-06 - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Shanghai EpimAb Biotherapeutics Co., Ltd. | 40 | 2021-05-20 | 2025-05-28 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Thrombosomes® in Bleeding Thrombocytopenic Patients Study Thrombosomes, Liquid Stored Platelets (LSP) - Thrombocytopenia, Hematologic Malignancy | Phase 2 | Terminated | Cellphire Therapeutics, Inc. | 21 | 2021-03-05 | 2023-05-25 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-01-15 | 2026-03-18 |
| Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis Infliximab, Intravenous Immunoglobulin Therapy, Prednisone - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 1 | 2021-01-07 | 2026-09-29 |
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Tocilizumab for Patients With Cancer and COVID-19 Disease Tocilizumab - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2020-05-28 | 2025-02-04 |
| Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 BMS-986253 - Solid Tumor, Sars-CoV2 | Phase 2 | Terminated | Columbia University | 43 | 2020-04-16 | 2025-05-22 |
| Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant Tagraxofusp-erzs - Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2020-03-27 | 2024-07-31 |
| Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. MB-102, Fludarabine, Cyclophosphamide - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Terminated | Mustang Bio | 3 | 2020-02-17 | 2024-07-22 |
| Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies ClinicMACs - Hematologic Malignancy | Phase 2 | Terminated | Dana-Farber Cancer Institute | 2 | 2020-01-21 | 2022-05-10 |
| Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases Supportive Palliative Care, Clinical Management, Best Practice - Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder | Phase 2 / Phase 3 | Terminated | Fred Hutchinson Cancer Center | 458 | 2019-08-15 | 2026-01-12 |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. T lymphocytes iCASP9 ΔCD19, Dimerizer drug AP1903 - Graft Versus Host Disease, Hematological Malignancies | Phase 1 / Phase 2 | Terminated | Centre Hospitalier Universitaire de Besancon | 2 | 2019-04-10 | 2025-07-09 |
| A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) Temferon - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Genenta Science | 9 | 2019-03-06 | 2022-01-28 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
Showing 20 of 80. Sign in to see all of them.
Myelodysplastic Syndromes (22) · Leukemia, Myeloid, Acute (19) · Myeloproliferative Disorders (15) · Polycythemia Vera (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Leukemia (14) · Lymphoma, Non-Hodgkin (14) · Multiple Myeloma (14) · Primary Myelofibrosis (14) · Lymphoma (11) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Thrombocythemia, Essential (10) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Hodgkin Disease (7)
Hemic and Lymphatic Diseases (80) · Neoplasms by Site (80) · Hematologic Diseases (77) · Neoplasms (76) · Neoplasms by Histologic Type (43) · Immune System Diseases (38) · Immunoproliferative Disorders (36) · Lymphoproliferative Disorders (36) · Bone Marrow Diseases (34) · Lymphatic Diseases (32) · Leukemia, Lymphoid (22) · Pathological Conditions, Signs and Symptoms (22) · Hemorrhagic Disorders (21) · Pathologic Processes (21)
Cyclophosphamide (17) · fludarabine phosphate (12) · fludarabine (11) · Whole-Body Irradiation (10) · Busulfan (7) · Stem Cell Transplantation (7) · Antilymphocyte Serum (6) · Cyclosporine (6) · Mycophenolic Acid (6) · Thiotepa (6) · Radiotherapy (5) · Tacrolimus (5) · thymoglobulin (5) · Filgrastim (4) · Granulocyte Colony-Stimulating Factor (4)
M.D. Anderson Cancer Center (10) · Fred Hutchinson Cancer Center (4) · Novartis Pharmaceuticals (4) · St. Jude Children's Research Hospital (4) · Mayo Clinic (3) · Baylor College of Medicine (2) · Bellicum Pharmaceuticals (2) · Bristol-Myers Squibb (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Incyte Corporation (2) · National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Alaunos Therapeutics (1) · Cellphire Therapeutics, Inc. (1)
United States (72) · Italy (8) · Canada (5) · France (5) · Spain (4) · Australia (3) · Belgium (3) · Germany (3) · Israel (3) · Netherlands (3) · United Kingdom (3) · Austria (2) · Czechia (2) · Belarus (1) · Bulgaria (1)
Brandon Triplett, MD (2) · Dolores Grosso, DNP, CRNP (2) · George Carrum, MD (2) · Neal Flomenberg, MD (2) · Ruben A. Mesa, MD (2) · Abhishek Maiti, MBBS (1) · Amer M Beitinjaneh, MD (1) · Amin Alousi, MD (1) · Ana G. Antun, MD, MSc (1) · Andrea Velardi, MD (1) · Andrew M Yeager, MD (1) · Ashok Srinivasan, MD (1) · Bipin N. Savani, MD (1) · Brandon M. Triplett, MD (1)
PMID 21874061, PMID 28602585, PMID 28622623, PMID 31527168, PMID 32896301, PMID 33027528, PMID 33568350, PMID 33580980, PMID 33792630, PMID 33795208, PMID 34255353, PMID 34474640, PMID 34933330, PMID 35226739, PMID 35750419, PMID 35941212, PMID 36841758, PMID 40373381, PMID 40979071, PMID 41043099
P30CA015083 (3), 2009 (2), 2017 (2), 2016 (1), P01CA078902 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), R01CA132197 (1), R01CA227092 (1), R21CA106177 (1), R34HL142322 (1), T32CA009515 (1), UG1CA189828 (1)